Metroprolol succinate Chemical Properties

Melting point:

136-138°C

storage temp. 

Hygroscopic, Refrigerator, under inert atmosphere

solubility 

Freely soluble in water, soluble in methanol, slightly soluble in ethanol (96 per cent), very slightly soluble in ethyl acetate.

form 

Solid

color 

White to Off-White

Stability:

Hygroscopic

InChI

InChI=1S/2C15H25NO3.C4H6O4/c2*1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3;5-3(6)1-2-4(7)8/h2*4-7,12,14,16-17H,8-11H2,1-3H3;1-2H2,(H,5,6)(H,7,8)

InChIKey

RGHAZVBIOOEVQX-UHFFFAOYSA-N

SMILES

C1(OCC(O)CNC(C)C)=CC=C(CCOC)C=C1.C(C(=O)O)CC(=O)O.C1(OCC(O)CNC(C)C)=CC=C(CCOC)C=C1

Safety Information

HS Code 

2922190900

Metroprolol succinate Usage And Synthesis

Description

Metoprolol succinate represents an entirely novel extended-release formulation of metoprolol, requiring administration only once daily to ensure constant metoprolol blood concentrations and sustained β1-adrenergic blocking effects throughout the 24-hour period. It offers numerous advantages in both pharmacology and clinical therapeutics. Clinically, it is primarily indicated for the management of hypertension,High blood pressure medication,angina pectoris, and stable chronic heart failure with left ventricular systolic dysfunction.
Administer orally once daily, preferably in the morning. Tablets may be divided but must not be chewed or crushed. Swallow with at least half a glass of liquid. Concomitant food intake does not affect bioavailability. Dosage should be individualised to avoid bradycardia. Effective dosing guidelines are as follows: Hypertension: 47.5–95 mg once daily. Patients unresponsive to 95 mg metoprolol succinate sustained-release tablets may combine with other antihypertensives, preferably diuretics and dihydropyridine calcium channel blockers, or increase dosage. Angina pectoris: 95–190 mg once daily. May be combined with nitrates or increased dosage as required.

Chemical Properties

White or almost white, crystalline powder.

History

Metoprolol Succinate, the world's first Beta-1 Selective Receptor blocker, was developed by AstraZeneca and first launched in 1992. It is commonly used in clinical practice to treat hypertension, angina pectoris, and stable chronic heart failure with impaired left ventricular systolic function.

Metoprolol was first developed in 1969 at Hassle Laboratories in Sweden. As a selective beta-1 adrenergic receptor blocker, it binds to beta-1 receptors to antagonize the effects of neurotransmitters and catecholamines on beta receptors. This action increases vascular smooth muscle sensitivity to vasoactive mediators and inhibits renin secretion. Clinically, it is used to treat hypertension, angina pectoris, and heart failure.

Uses

Anti - hypertensives

Uses

Metoprolol Succinate is used in the treatment of patients suffering from chronic heart failure, as well as to treat blood pressure from mild hypertension. β-adrenoceptor antagonist or β-blocker.

Definition

ChEBI: Metoprolol succinate is an alcohol and a member of phenols.

brand name

Toprol (AstraZeneca).

in vivo

IC 50

β1 adrenoceptor

Metroprolol succinate(98418-47-4)Related Product Information

• Dioctyl sulfosuccinate sodium salt
• 1-(2-methoxyethyl)-4-nitrobenzene
• 3-[4-(2-Methoxyethyl)phenoxy]-
• 1,3-Bis[(1-Methylethyl)aMino]-2-propanol Dihydrochloride
• Bestatin
• Melatonine
• Losartan potassium
• Disodium succinate
• Titanium tetraisopropanolate
• 6alpha-Methylprednisolone sodium succinate
• Succinic acid
• Metoprolol
• Metoprolol tartrate
• iron succinate
• Metoprolol
• O-Desmethyl Metoprolol
• Metroprolol succinate
• Metoprolol Succinate